Cell Viability Assays Market Outlook:
Cell Viability Assays Market size was over USD 2.68 billion in 2025 and is poised to exceed USD 6.46 billion by 2035, growing at over 9.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of cell viability assays is estimated at USD 2.9 billion.
The market growth is due to growing interest in developing cell therapy technologies for the treatment of COVID-19 and its increasing acceptance. For example, in 2020, Calidi Biotherapeutics Inc. announced that the Food and Drug Administration had granted provisional marketing authorization for its partner Personalized Stem Cells Inc.'s Investigational New Product Application to be used with stem cell therapy on COVID-19 and pneumonia patients. COVID-19 was reported to WHO by 761,769,759 confirmed cases including 6,784,181 deaths across the globe.
In addition, investment in the area of cell-based research and funding has increased. For example, the California Center for Regenerative Medicine said in February 2022 that it would invest around USD 10 million on a cell therapy study to help patients who have throat cancer recover from terrible radiation side effects.
